Latest news with #anti-blindness
Yahoo
23-05-2025
- Health
- Yahoo
Bayer wins EU watchdog's endorsement for longer Eylea treatment intervals
(Reuters) -German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of its anti-blindness treatment Eylea, giving it a potential edge over Roche's rival treatment Vabysmo. Bayer said in a statement the European Medicines Agency recommended that eye drug Eylea, at a high dose of 8 mg, can be injected at intervals of up to six months to treat wet age-related macular degeneration and diabetic macular oedema. Bayer shares were up 2.5% at 0717 GMT, surpassing a gain of 0.7% in the Stoxx Europe 600 Health Care index. Eylea, an injection against the leading causes of blindness among the elderly, is currently approved in the EU for treatment intervals of up to five months. Bayer has developed it jointly with Regeneron. Vabysmo, a major driver of revenue growth for Switzerland's Roche, is cleared to be given at intervals of up to four months. The EU commission has the final say on drug approval but it typically follows the medicines agency's opinions. Bayer said that decision is expected within the next few weeks. Sign in to access your portfolio
Reuters
23-05-2025
- Business
- Reuters
Bayer wins EU watchdog's endorsement for longer Eylea treatment intervals
May 23 (Reuters) - German drugmaker Bayer ( opens new tab on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of its anti-blindness treatment Eylea, giving it a potential edge over Roche's (ROG.S), opens new tab rival treatment Vabysmo. Bayer said in a statement the European Medicines Agency recommended that eye drug Eylea, at a high dose of 8 mg, can be injected at intervals of up to six months to treat wet age-related macular degeneration and diabetic macular oedema. Bayer shares were up 2.5% at 0717 GMT, surpassing a gain of 0.7% in the Stoxx Europe 600 Health Care index. Eylea, an injection against the leading causes of blindness among the elderly, is currently approved in the EU for treatment intervals of up to five months. Bayer has developed it jointly with Regeneron (REGN.O), opens new tab. Vabysmo, a major driver of revenue growth for Switzerland's Roche, is cleared to be given at intervals of up to four months. The EU commission has the final say on drug approval but it typically follows the medicines agency's opinions. Bayer said that decision is expected within the next few weeks.
Jordan Times
08-05-2025
- Health
- Jordan Times
MAP Jordan, partners deliver vision care to over 2,000 patients since 2024
The Jordan Medical Aid for Palestinians, in partnership with Al Basar International Foundation and Al Khansa Hospital, concludes the fourth and fifth phases of its ongoing anti-blindness campaign (Photo courtesy of Jordan Medical Aid for Palestinians) AMMAN — The Jordan Medical Aid for Palestinians (MAP Jordan), in partnership with Al Basar International Foundation and Al Khansa Hospital, has concluded the fourth and fifth phases of its ongoing anti-blindness campaign, delivering 930 free cataract surgeries to patients living in refugee camps across the Kingdom. With this latest effort, the total number of surgeries performed since the campaign launched in January 2024 has reached 2,250. Earlier phases saw 399 surgeries in the first round, followed by 923 across the second and third, according to a MAP Jordan statement. In the fourth and fifth phases alone, over 8,000 individuals were screened. Alongside the surgeries, patients received free eye drops and prescription eyeglasses—part of a comprehensive initiative aimed at enhancing vision care and improving the quality of life for underserved communities. 'This initiative goes beyond numbers,' said Islam Mohamad, program supervisor at MAP Jordan. 'Each surgery tells a story of transformation, children seeing their parents clearly for the first time, young adults returning to work and education, and elderly individuals regaining their independence. It's about restoring dignity, hope, and a sense of purpose.' The success of the campaign reflects the deep partnership between MAP Jordan and its partners, as well as the support of donors and volunteers who continue to fuel the mission, according to the statement. Plans are already underway for future campaigns as part of the long-term vision to eliminate preventable blindness across Jordan's refugee populations, the statement said.
